Evidence map›Paper›PMID 41463490›Full record

ArticleBiology2025

Evaluation of HLA Region-Specific High-Throughput Sequencing FASTQ Reads Combined with Ensemble HLA-Typing Tools for Rapid and High-Confidence HLA Typing.

Vijay G Padul, Mini Gill, Jesus A Perez, Javier J Lopez, Santosh Kesari, Shashaanka Ashili

Abstract read
In one paragraph

Article in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vijay G PadulRhenix Lifesciences, Hyderabad 500038, Telangana, India.
Mini GillCureScience, 5820 Oberlin Dr., 202, San Diego, CA 92121, USA.
Jesus A PerezMedicine, Pan American Cancer Treatment Center, Tijuana 22010, Mexico.ORCID 0000-0002-7431-9319
Javier J LopezNeurology, Pan American Cancer Treatment Center, Tijuana 22010, Mexico.
Santosh KesariAsthra Health, Santa Monica, CA 90403, USA.ORCID 0000-0003-3772-6000
Shashaanka AshiliKrebs Neumann, Cypress, TX 77433, USA.ORCID 0000-0001-6335-0954

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate human leukocyte antigen (HLA) genotyping is a critical step in the implementation of neoantigen peptide-based cancer immunotherapy. Existing computational tools for HLA genotyping using high-throughput sequencing data often lack sufficient accuracy when used individually. Employing an ensemble of multiple software tools and sequencing sources can potentially address this limitation; however, this approach is hindered by increased processing time.

methodsWe evaluated an ensemble method that utilizes four HLA-genotyping software tools applied to three sequencing sources-tumor exome, normal exome, and tumor RNA-seq-from the same individual to achieve high-confidence HLA genotyping. To reduce processing time, we incorporated an HLA region-specific FASTQ read-filtering strategy. With this protocol we also provide a Docker implementation of the FASTQ read-filtering pipeline and a software tool for the analysis of HLA genotypes.

resultsConsensus HLA genotypes for HLA class I alleles, derived from filtered FASTQ files, showed complete concordance with those obtained from unfiltered original FASTQ files. The use of filtered FASTQ files significantly reduced the time required for HLA genotyping.

conclusionsThese findings demonstrate the utility of the proposed HLA genotyping approach in achieving rapid and high-confidence two-field HLA genotyping.

Indexed as

cancer genomicsHLA genotypingHLA high-throughput sequencingHLA typingneoantigen peptidespersonalized cancer immunotherapy

Identifiers

PMID41463490
PMCPMC12731231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.